Tasigna nilotinib regulatory update

Swissmedic approved Tasigna nilotinib from Novartis for first-line treatment of Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) in chronic phase. The BCR-ABL tyrosine kinase i...